Fireside Chat with Dyne Therapeutics on DYNE-251

Moving from Bench to Clinic to Deliver a Potentially Transformative Therapy for Duchenne Muscular Dystrophy Join us for a Fireside Chat discussing Dyne’s Phase 1/2 clinical trial, DELIVER, evaluating DYNE-251 […]

Clinical Hold of DYNE-251

On January 14th 2022, the U.S. FDA placed a clinical hold on Dyne’s Investigational New Drug (IND) submission for the launch of their clinical trial of DYNE-251, which targets Duchenne […]


Dyne Therapeutics Series B financing

CureDuchenne congratulates the incredible Dyne Therapeutics team, who recently announced closing $115M in equity financing to develop transformational therapies for patients with serious muscle diseases. We share this news in […]